Ningxia Zhongke Biotechnology Co (SHSE:600165) Total Operating Expense: ¥116.2 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600165 Ningxia Zhongke Biotechnology Co Ltd SHSE:600165
53 GF Score
Price ¥2.43
GF Value ¥2.77
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ningxia Zhongke Biotechnology Co Total Operating Expense?

Ningxia Zhongke Biotechnology Co SHSE:600165 +9.95% 53 Total Operating Expense is ¥116.2 Mil as of Mar. 2026. GuruFocus rates SHSE:600165 with a GF Score™ of 53/100 and a GF Value™ of ¥2.77 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Ningxia Zhongke Biotechnology Co's Total Operating Expense for the three months ended in Mar. 2026 was ¥20.8 Mil. Ningxia Zhongke Biotechnology Co's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥116.2 Mil.

Ningxia Zhongke Biotechnology Co Total Operating Expense Related Terms

Ningxia Zhongke Biotechnology Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Ningxia Zhongke Biotechnology Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningxia Zhongke Biotechnology Co Total Operating Expense Chart

Ningxia Zhongke Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.53 131.28 67.87 80.09 113.32

Ningxia Zhongke Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.90 22.41 34.42 38.58 20.82
SHSE:600165
53GF Score
Ningxia Zhongke Biotechnology Co Ltd SHSE:600165
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningxia Zhongke Biotechnology Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥116.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ¥116.2 Mil mean?
Ningxia Zhongke Biotechnology Co (SHSE:600165) has a Total Operating Expense of ¥116.2 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ningxia Zhongke Biotechnology Co and its competitors.
Is Ningxia Zhongke Biotechnology Co's Total Operating Expense too high?
Ningxia Zhongke Biotechnology Co's current Total Operating Expense is ¥116.2 Mil. Overall, Ningxia Zhongke Biotechnology Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ningxia Zhongke Biotechnology Co's Total Operating Expense compare to LIN and SHW?
Ningxia Zhongke Biotechnology Co's Total Operating Expense of ¥116.2 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Chemicals company?
A good Total Operating Expense depends on the Chemicals industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ningxia Zhongke Biotechnology Co and its competitors. Ningxia Zhongke Biotechnology Co's current Total Operating Expense is ¥116.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningxia Zhongke Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co (SHSE:600165) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥2.77, compared to a current price of ¥2.43 — trading 12.3% below its estimated fair value. The current Total Operating Expense is ¥116.2 Mil. Ningxia Zhongke Biotechnology Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Ningxia Zhongke Biotechnology Co (SHSE:600165), the current Total Operating Expense is ¥116.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningxia Zhongke Biotechnology Co (SHSE:600165) Overvalued in 2026?

Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co stock appears to be undervalued. The current stock price of ¥2.43 is trading 12.3% below its estimated GF Value™ of ¥2.77. GuruFocus considers Ningxia Zhongke Biotechnology Co to be Modestly Undervalued.

Key valuation signals for SHSE:600165:

  • Total Operating Expense: ¥116.2 Mil
  • GF Value™: ¥2.77 vs. price of ¥2.43 (12.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600165 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningxia Zhongke Biotechnology Co Business Description

Address Hebin Street, Ningxia Hui Autonomous Region, Huinong District, Shizuishan, CHN, 750002
Ningxia Zhongke Biotechnology Co Ltd is engaged in the production and sales of activated carbon products, preparation and storage of stem cells, trade and other businesses, as well as lauric acid.
53GF Score

Get the complete analysis for SHSE:600165

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥2.43
Price
¥2.77
GF Value